2023 Volume 69 Issue 1 Pages 1-7
BACKGROUND: The use of cryoprecipitate, characterized by high fibrinogens content and hemostatic efficacy, for dilution and consumption coagulopathy associated with massive bleeding has expanded in recent years. To date, however, no recommendations or suggestions for the use of cryoprecipitate plasma have yet appeared.
Here, we investigated the status of transfusion therapy using cryoprecipitate plasma.
METHODS: Cases receiving cryoprecipitate between January 2015 and January 2018 were retrospectively evaluated, and analyzed with regard to the use of cryoprecipitate and cryoprecipitate plasma, and factors affecting the use of cryo-supernatant plasma in combination.
RESULTS: 676 bags of cryoprecipitate were supplied to 161 patients and 620 bags were used. The number of cases using cryoprecipitate plasma/cryoprecipitate was 237/524 bags for surgeries using CPB, 18/80 bags for surgeries not using CPB, and 1/16 bags for non-surgery; and cases with compatible and heterocompatible blood were 44/59 and 58/102. On multivariate analysis, heterozygous compatible transfusion was significantly associated with a reduced rate of concomitant use of cryo-supernatant plasma (OR: 0.45, 95%CI: 0.22-0.90, p<0.02).
CONCLUSION: Use of minor-ABO-incompatible cryoprecipitate was associated with a decrease in the concomitant use of cryo-supernatant plasma. Given its potential to increase plasma volume, further investigation of the use and efficacy of cryo-supernatant plasma is warranted.
